 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
21 June 2005 | Volume 142 Issue 12 Part 1 | Pages 963-967
Background: Prospective data defining the clinical course in idiopathic pulmonary fibrosis (IPF) are sparse.
Objective: To analyze the clinical course of patients with mild to moderate IPF.
Design: Analysis of data from the placebo group of a randomized, controlled trial evaluating interferon-
Setting: Academic and community medical centers.
Patients: 168 patients in the placebo group of a trial evaluating interferon-
Measurements: Measures of physiology and dyspnea assessed at 12-week intervals; hospitalizations; and the pace of deterioration and cause of death over a median period of 76 weeks.
Results: Physiologic variables changed minimally during the study. However, 23% of patients required hospitalization for a respiratory disorder and 21% died. Idiopathic pulmonary fibrosis was the primary cause of death in 89% of patients who died, and an apparent acute clinical deterioration preceded death in 47% of these patients.
Limitations: The instrument used to define the pace of deterioration and cause of death was applied retrospectively.
Conclusions: Recognition of the common occurrence of acute fatal deterioration in patients with mild to moderate IPF has important implications for monitoring patients and supports early referral for lung transplantation.
*A complete list of the IPF Study Group is available from reference 3: Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125-33.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From University of Michigan, Ann Arbor, Michigan; InterMune, Inc., Brisbane, California; Policy Analysis, Inc., Brookline, Massachusetts; University of California, San Francisco, San Francisco, California; Duke University School of Medicine, Durham, North Carolina; Yale University, New Haven, Connecticut; University of Washington, Seattle, Washington; and National Jewish Medical and Research Center, Denver, Colorado.
Grant Support: By InterMune, Inc.
Potential Financial Conflicts of Interest: Employment: K.M. Starko (InterMune), W.Z. Bradford (InterMune); Consultancies: F.J. Martinez (InterMune), T.E. King (InterMune), D.A. Schwartz (InterMune), P.W. Noble (InterMune, Genzyme Millenium), G. Raghu (InterMune), K.K. Brown (InterMune, Wyeth, Actelion, Genzyme Corp., FibroGen); Honoraria: T.E. King (InterMune), P.W. Noble (InterMune), G. Raghu (InterMune), K.K. Brown (InteMune, Wyeth, Actelion, Genzyme Corp., FibroGen); Stock ownership or options (other than mutual funds): S. Safrin (InterMune), K.M. Starko (InterMune), W.Z. Bradford (InterMune); Patents pending: K.M. Starko (InterMune), W.Z. Bradford (InterMune).
Requests for Single Reprints: Fernando Martinez, MD, Department of Internal Medicine, University of Michigan, 3916 Taubman Centers 0360, Ann Arbor, MI 48109; e-mail, fmartine{at}med.umich.edu.
Current Author Addresses: Dr. Martinez: Department of Internal Medicine, University of Michigan, 3916 Taubman Centers 0360, Ann Arbor, MI 48109.
Drs. Safrin, Starko, and Bradford: InterMune, Inc., 3280 Bayshore Boulevard, Brisbane, CA 94005.
Dr. Weycker: Policy Analysis Inc., Four Davis Court, Brookline, MA 02445.
Dr. King: Department of Medicine, San Francisco General Hospital, 5H22, 1001 Potrero Avenue, San Francisco, CA 94110.
Dr. Flaherty: University of Michigan Health System, 1500 East Medical Center Drive, 3916 Taubman Center, Ann Arbor, MI 48109.
Dr. Schwartz: Duke University Medical Center, Box 2629, Research Drive, MSRB Room 275, Durham, NC 27710.
Dr. Noble: Pulmonary and Critical Care Medicine, Yale School of Medicine, TAC 441-C, 333 Cedar Street, New Haven, CT 06525.
Dr. Raghu: Division of Pulmonary, University of Washington, BB 1237 Health Sciences, Box 356522, Seattle, WA 98195.
Dr. Brown: National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206.
Author Contributions: Conception and design: F.J. Martinez, S. Safrin, D. Weycker, K.M. Starko, W.Z. Bradford, D.A. Schwartz, P.W. Noble, G. Raghu, K.K. Brown.
Analysis and interpretation of the data: F.J. Martinez, S. Safrin, D. Weycker, K.M. Starko, W.Z. Bradford, T.E. King Jr., P.W. Noble, G. Raghu, K.K. Brown.
Drafting of the article: F.J. Martinez, S. Safrin, D. Weycker, K.M. Starko, W.Z. Bradford, D.A. Schwartz, P.W. Noble, K.K. Brown.
Critical revision of the article for important intellectual content: F.J. Martinez, S. Safrin, D. Weycker, K.M. Starko, T.E. King Jr., K.R. Flaherty, D.A. Schwartz, P.W. Noble, G. Raghu, K.K. Brown.
Final approval of the article: F.J. Martinez, S. Safrin, D. Weycker, K.M. Starko, T.E. King Jr., K.R. Flaherty, D.A. Schwartz, P.W. Noble, G. Raghu, K.K. Brown.
Provision of study materials or patients: F.J. Martinez, K.R. Flaherty, D.A. Schwartz, K.K. Brown.
Statistical expertise: F.J. Martinez, D. Weycker. ARTICLE
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
1b. 1b.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  C. E. Daniels, E. S. Yi, and J. H. Ryu Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis Eur. Respir. J., July 1, 2008; 32(1): 170 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Collard and F. J. Martinez Basis of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Japanese Patients Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1398 - 1398. [Full Text] [PDF]
|
|
|
|
|
|
T. R. McMillan, B. B. Moore, J. B. Weinberg, K. M. Vannella, W. B. Fields, P. J. Christensen, L. F. van Dyk, and G. B. Toews Exacerbation of Established Pulmonary Fibrosis in a Murine Model by Gammaherpesvirus Am. J. Respir. Crit. Care Med., April 1, 2008; 177(7): 771 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W A Wuyts, M Thomeer, L J Dupont, and G M Verleden An algorithm for referral of patients with IPF for lung transplantation Thorax, March 1, 2008; 63(3): 292 - 292. [Full Text] [PDF]
|
|
|
|
|
|
K. R. Flaherty High-Resolution Computed Tomography and the Many Faces of Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., February 15, 2008; 177(4): 367 - 368. [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Moore and C. M. Hogaboam Murine models of pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L152 - L160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Antoniou, D. M. Hansell, M. B. Rubens, K. Marten, S. R. Desai, N. M. Siafakas, A. G. Nicholson, R. M. du Bois, and A. U. Wells Idiopathic Pulmonary Fibrosis: Outcome in Relation to Smoking Status Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 190 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Tzelepis, S. P. Toya, and H. M. Moutsopoulos Occult connective tissue diseases mimicking idiopathic interstitial pneumonias Eur. Respir. J., January 1, 2008; 31(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Raymond, M. Schaller, C. M. Hogaboam, N. W. Lukacs, R. Rochford, and S. L. Kunkel Toll-like Receptors, Notch Ligands, and Cytokines Drive the Chronicity of Lung Inflammation Proceedings of the ATS, December 1, 2007; 4(8): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Konigshoff, A. Wilhelm, A. Jahn, D. Sedding, O. V. Amarie, B. Eul, W. Seeger, L. Fink, A. Gunther, O. Eickelberg, et al. The Angiotensin II Receptor 2 Is Expressed and Mediates Angiotensin II Signaling in Lung Fibrosis Am. J. Respir. Cell Mol. Biol., December 1, 2007; 37(6): 640 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hyzy, S. Huang, J. Myers, K. Flaherty, and F. Martinez Acute Exacerbation of Idiopathic Pulmonary Fibrosis Chest, November 1, 2007; 132(5): 1652 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Collard, B. B. Moore, K. R. Flaherty, K. K. Brown, R. J. Kaner, T. E. King Jr., J. A. Lasky, J. E. Loyd, I. Noth, M. A. Olman, et al. Acute Exacerbations of Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 636 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. O. Rosas, P. Ren, N. A. Avila, C. K. Chow, T. J. Franks, W. D. Travis, J. P. McCoy Jr., R. M. May, H.-P. Wu, D. M. Nguyen, et al. Early Interstitial Lung Disease in Familial Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 698 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. T. Bates, G. S. Davis, A. Majumdar, K. J. Butnor, and B. Suki Linking Parenchymal Disease Progression to Changes in Lung Mechanical Function by Percolation Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 617 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Brown Roger S. Mitchell Lecture. Rheumatoid Lung Disease Proceedings of the ATS, August 15, 2007; 4(5): 443 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Noth and F. J. Martinez Recent Advances in Idiopathic Pulmonary Fibrosis Chest, August 1, 2007; 132(2): 637 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Parambil, J. L. Myers, M.-C. Aubry, and J. H. Ryu Causes and Prognosis of Diffuse Alveolar Damage Diagnosed on Surgical Lung Biopsy Chest, July 1, 2007; 132(1): 50 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nathan, P. W. Noble, and R. M. Tuder Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 875 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Sweet, M. G. Patti, L. E. Leard, J. A. Golden, S. R. Hays, C. Hoopes, and P. R. Theodore Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 1078 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gunther, B. Enke, P. Markart, P. Hammerl, H. Morr, J. Behr, G. Stahler, W. Seeger, F. Grimminger, I. Leconte, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study Eur. Respir. J., April 1, 2007; 29(4): 713 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Wells and C. M. Hogaboam Update in Diffuse Parenchymal Lung Disease 2006 Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 655 - 660. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Kreider, J. Hansen-Flaschen, N. N. Ahmad, M. D. Rossman, L. R. Kaiser, J. C. Kucharczuk, and J. B. Shrager Complications of Video-Assisted Thoracoscopic Lung Biopsy in Patients with Interstitial Lung Disease Ann. Thorac. Surg., March 1, 2007; 83(3): 1140 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nathan, O. A. Shlobin, S. Ahmad, S. Urbanek, and S. D. Barnett Pulmonary Hypertension and Pulmonary Function Testing in Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 657 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hamada, S. Nagai, S. Tanaka, T. Handa, M. Shigematsu, T. Nagao, M. Mishima, M. Kitaichi, and T. Izumi Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung as Prognosticator in Patients With Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. O. Rosas and N. Kaminski When It Comes to Genes--IPF or NSIP, Familial or Sporadic--They're All the Same Am. J. Respir. Crit. Care Med., January 1, 2007; 175(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Studer and N. Kaminski Towards Systems Biology of Human Pulmonary Fibrosis Proceedings of the ATS, January 1, 2007; 4(1): 85 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Tiitto, R Bloigu, U Heiskanen, P Paakko, V L Kinnula, and R Kaarteenaho-Wiik Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia Thorax, December 1, 2006; 61(12): 1091 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Cottin Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur. Respir. J., November 1, 2006; 28(5): 893 - 896. [Full Text] [PDF]
|
|
|
|
 |
|
 O.J. Dempsey, K.M. Kerr, L. Gomersall, H. Remmen, and G.P. Currie Idiopathic pulmonary fibrosis: an update QJM, October 1, 2006; 99(10): 643 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Raghu, D. Weycker, J. Edelsberg, W. Z. Bradford, and G. Oster Incidence and Prevalence of Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 810 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Flaherty, A.-C. Andrei, S. Murray, C. Fraley, T. V. Colby, W. D. Travis, V. Lama, E. A. Kazerooni, B. H. Gross, G. B. Toews, et al. Idiopathic Pulmonary Fibrosis: Prognostic Value of Changes in Physiology and Six-Minute-Walk Test Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 803 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Raghu Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. Eur. Respir. J., September 1, 2006; 28(3): 463 - 465. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Antoniou, A. G. Nicholson, M. Dimadi, K. Malagari, P. Latsi, A. Rapti, N. Tzanakis, R. Trigidou, V. Polychronopoulos, and D. Bouros Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis Eur. Respir. J., September 1, 2006; 28(3): 496 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Crowley, P. Kelly, and J. J. Egan Acute Exacerbations in Idiopathic Pulmonary Fibrosis Ann Intern Med, February 7, 2006; 144(3): 218 - 218. [Full Text] [PDF]
|
|
|
|
|
|
D. S. Kim, H. R. Collard, and T. E. King Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proceedings of the ATS, January 1, 2006; 3(4): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Martinez and K. Flaherty Pulmonary function testing in idiopathic interstitial pneumonias. Proceedings of the ATS, January 1, 2006; 3(4): 315 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Walter, H. R. Collard, and T. E. King Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Acute Deterioration in Idiopathic Pulmonary Fibrosis Journal Watch (General), July 26, 2005; 2005(726): 3 - 3. [Full Text]
|
|
Read all Rapid Responses
Article
